Zosurabalpin is an experimental antibiotic developed in a collaboration between the pharmaceutical company Roche and scientists from Harvard University, for the treatment of carbapenem-resistant Acinetobacter baumannii. From Wikipedia
The study will enroll about 400 patients worldwide to evaluate a drug that disrupts the superbug’s protective membrane
